July 2, 2010 (Munich, Germany) — Results of 2 related trials investigating the effects of statins on urinary protein excretion and kidney function found atorvastatin (ATV) protective and rosuvastatin (RSV) unprotective, and possibly harmful, in diabetic and nondiabetic patients.
In findings likely to make it easier and faster for stem cell biologists to generate patient-specific embryonic-like stem cells, researchers at Children's Hospital Boston have reprogrammed adult blood cells into induced pluripotent stem (iPS) cells.
Intercell's investigational vaccine enhancement patch system for avian H5N1 influenza has failed a Phase II study. The company is working under a contract with Human and Health services (HHS) to develop a dose-sparing approach with potential for a single dose immunization combining a H5N1 vaccine with Intercell's LT adjuvant patch.
The 62nd Indian Pharmaceutical Congress (IPC), hosted by Indian Hospital Pharmacists’ Association (IHPA), will be held from December 17 to 19, 2010 in Manipal University.
June 6, 2010 (Chicago, Illinois) — An experimental therapy for advanced melanoma has been shown to improve overall survival in patients, and is "on the road" to becoming the "new standard of care," said one of its investigators here at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting.
Liquidity crunch and growing uncertainty in the Euro zone have not deterred the Karnataka-based pharma companies from expanding their operations and also patent filing in Europe.
Aiming to understand the potential health benefits of rotavirus vaccination and also to develop a national representative data on rotavirus burden and strains in India, the Indian Council of Medical Research (ICMR) will soon embark on task force projects on burden of rotavirus diarrhoea in India under the Indian Rotavirus Surveillance Network.
Although the department of AIDS Control under the Union health ministry has exhausted its allocation almost completely, it failed to achieve the physical targets set for the last financial year.
Amylin Pharmaceuticals, Inc, Eli Lilly and Company and Alkermes, Inc announced that the US Food and Drug Administration (FDA) has classified the Bydureon (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.
Copyright © 2008-2019, PharmaTutor Edu Labs
Recent Topics